Physician profile
Srutha Rajkumar
NPI 1801887914
$2,758.32
in general payments reported to CMS, 2019-2025
22 companies · $663 in 2025
The $663 reported for 2025 was more than what 75% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $307 · 2020: $139 · 2021: $347 · 2022: $343 · 2023: $580 · 2024: $379 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,622.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $360.24 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $312.98 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $247.12 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $243.27 | 2021-2025 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $240.58 | 2020-2023 | Trintellix |
| Abbvie INC. | $217.23 | 2023-2025 | |
| Alkermes, INC. | $212.82 | 2019-2023 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $169.69 | 2019-2025 | Spravato, Invega Sustenna |
| Neos Therapeutics, Lp | $167.19 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $151.06 | 2019-2024 | Jornay Pm |
| Adlon Therapeutics L.P. | $133.95 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $74.33 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $50.78 | 2025 | Austedo Xr, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.48 | 2024-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $30.84 | 2023-2025 | Ingrezza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orexo US, INC. | $16.75 | 2023 | Zubsolv |
| Bausch Health US, LLC | $16.48 | 2022 | |
| Shire North American Group INC | $15.00 | 2019 | |
| Vertical Pharmaceuticals, LLC | $14.57 | 2025 | Relexxii |
| Sage Therapeutics, LLC | $14.21 | 2025 | Zurzuvae |
| Supernus Pharmaceuticals, INC. | $14.21 | 2025 | Qelbree |
| Jazz Pharmaceuticals INC. | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srutha Rajkumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.